Geistlich Pharma commits to sustainability
Wolhusen - Geistlich Pharma has declared sustainability to be a priority for the company. To this end, it has undergone the Swiss Triple Impact program. Its biomaterial production site in Wolhusen is to be climate neutral by 2030.
Geistlich Pharma, a family-owned company based in Wolhusen in the canton of Lucerne, has declared sustainability to be a priority. According to a press release, it has undergone the Swiss Triple Impact (STI) program initiated by B Lab Switzerland. This program enables Swiss companies to measure their contribution to the United Nations’ Sustainable Development Goals (SDG) and thus improve their sustainability performance.
As a member of the STI Directory, Geistlich has pledged itself via a commitment letter to ensuring that annually more than 500 dentists receive ongoing high-quality dental education in regenerative dentistry, free of cost, by 2025. Ralf Halbach, CEO of Geistlich Pharma AG, commented: “By joining the Swiss Triple Impact as a Directory Leader, we aim to improve the health of patients worldwide, especially in developing countries.” As a leading regeneration expert in the field of dentistry with over 750 employees worldwide, Geistlich hopes to quantify the ecological, social, and economic impact of its work.
Geistlich plans to ensure that the production site for Geistlich biomaterials in Wolhusen is climate neutral by 2030. In another step, Geistlich plans to increase the number of women in its management team and is aiming for gender parity by 2030.
Geistlich Pharma has headquarters in the canton of Lucerne and is part of the Geistlich Group, which is headquartered in Schlieren in the canton of Zurich.
